Reven today announced that three new members with extensive experience and knowledge in clinical research and quality assurance have joined its multi-disciplinary team to work on the COVID-19 clinical project … Read More
News
Latest News
Reven Selects E-Clinical Services Provider DSG for Clinical Data Management Services
Reven is planning to initiate a randomized, double-blind, placebo-controlled, multi-institutional clinical trial of its lead anti-inflammatory/anti-oxidant investigational drug product Rejuveinix (RJX) in the treatment of COVID-19. … Read More
Reven Selects APCER Life Sciences as Its Service Provider in Pharmacovigilance, Safety Monitoring, Quality Assurance and Regulatory Affairs for Its Upcoming COVID-19 Clinical Trial
Reven today announced that it selected the global specialty drug safety services provider APCER Life Sciences (APCER) as its preferred vendor to provide pharmacovigilance (PVG), safety monitoring, quality assurance and … Read More
US Patent and Trademark Office Allows Reven’s Patent Application to Issue as a New Patent
Reven today announced that it received a formal Notice of Allowance from the US Patent and Trademark Office regarding its patent application entitled: “Compositions and Methods for the Prevention and Treatment of Cardiovascular Disease … Read More
Reven’s Patented, First-in-Class Anti-inflammatory Treatment Platform for Sepsis on Track for Clinical Testing in COVID-19 Patients
Reven had recently submitted a Pre-Investigational New Drug (Pre-IND) application to the U.S. Food and Drug Administration (FDA) to obtain feedback and guidance for its clinical evaluation of the anti-inflammatory/anti-oxidant investigational drug product Rejuveinix (RJX) in the treatment of COVID-19. Reven today announced that FDA has responded favorably to its Pre-IND application … Read More
Reven Publishes New COVID-19 Related Articles Outlining Clinical Impact Potential of Its RJX Platform
Reven today announced the publication of two peer-reviewed expert articles authored by its Chief Medical Officer & Chief Scientific Officer, Fatih Uckun M.D. Ph.D., and other members of the Reven team and their academic collaborators in the medical journal, Clinical Investigation (London) … Read More
Reven Announces the Appointment of Eminent Physician-Scientist Fatih M. Uckun, M.D. Ph.D., Internationally Recognized for his Seminal Contributions to Oncology, Immunology and Immunity, as its Chief Medical Officer and Chief Scientific Officer
In his new position at Reven, Dr. Uckun will provide executive oversight for Reven’s global Research & Development and clinical programs. In addition, Dr. Uckun will contribute medical-scientific leadership and direction for Reven’s basic and translational research activities … Read More
Rejuveinix (RJX) as a drug candidate for patients with systemic inflammatory response syndrome (SIRS): Supportive care considerations for COVID-19, cancer, and sepsis
Sepsis is the consequence of a systemic host inflammatory response to an infection with bacteria, fungi or viruses that is further associated with profound metabolic alterations (1-9). Severe sepsis is frequently associated
with septic shock … Read More
Reven Announces COVID-19 related Acute Respiratory Distress Syndrome (ARDS) Regulatory Update
Golden, Colorado, Thursday, June 11, 2020 1:00am MDT – Reven, LLC, a biopharmaceutical company that is developing Rejuveinix (RJX) for patients with cardiovascular and other health conditions, announced today that it recently completed an animal study in connection with its … Read More
Reven Announces the Appointment of Jeffrey Halverson as Chief Financial Officer
Mr. Halverson joins Reven with broad experience in finance, most recently as the Founder, President and Chief Executive Officer of American Sky Financial, a Commercial and Residential Mortgage company serving community banks and developers nationwide. … Read More
Reven Announces the Appointment of Michael Volk as Chief Strategy Officer
Golden, Colorado, Thursday, April 22, 2020 1:00am MDT – Reven, LLC, a biopharmaceutical company that is developing a new drug called Rejuveinix (RJX) for patients suffering cardiovascular and other health conditions, announced today that Michael Volk, Co-Founder, will be stepping … Read More
Reven Announces Coronavirus Treatment Acceleration Program (CTAP) Submission to the FDA
Golden, Colorado, Friday, April 3, 2020 3:00pm MDT – Reven, LLC, a biopharmaceutical company that is developing its flagship product Rejuveinix (RJX) for patients with vascular and metabolic related health conditions, announced today that it has submitted a proposal to … Read More
2020/03/28 Reven News Press
A Phase 1, Double-blind, Placebo-controlled, Randomized, Two-Part, Ascending Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Rejuveinix (RJX) in Healthy Participants. Click here for the full study details
2020/03/23 Reven News Press
Reven successfully completes Phase I clinical trials and is pleased to announce completion with no Serious Adverse Events and no Unexpected Adverse Events. Results are expected to be submitted to the FDA during the next few weeks.
2020/03/22 Reven News Press
Reven announces Phase II Clinical Development plans for upcoming human efficacy trials. These trials include exploring efficacy as an adjunct therapy for patients suffering Critical Limb Ischemia. Additional areas of focus in separate trials will be for chronic wound healing … Read More